Ignite Creation Date:
2024-05-05 @ 11:58 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00191659
Status:
COMPLETED
Last Update Posted:
2007-03-02
First Post:
2005-09-12
Brief Title:
Study of Broader Efficacy of Atomoxetine in the Treatment of ADHD in ChildrenAdolescents
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
A Randomised Controlled Open-Label Study of the Broader Efficacy of Atomoxetine Hydrochloride in the Treatment of Attention-DeficitHyperactivity Disorder ADHD in Children and Adolescents
Status:
COMPLETED
Status Verified Date:
2007-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To test the hypothesis that childrenadolescents with ADHD who are treated with atomoxetine hydrochloride in comparison to standard current therapies have greater improvements in their quality of life
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| B4Z-BP-LYBS | None | None | None |